Thorium dioxide (Thorotrast)

Myelodysplastic disorderits - Thorium dioxide (Thorotrast) Factor

Last reviewed for CCPS 08 January 2007.

Preliminary questions [36994]

36772 [1] there is some evidence that thorium dioxide (Thorotrast) may be a factor in the development of the condition under consideration.

36773 [1] the veteran has received thorium dioxide (Thorotrast) at some time.

37018 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and VEA service for the clinical onset of myelodysplastic disorder.

37020 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and eligible service for the clinical onset of myelodysplastic disorder.

or

37019 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and operational service for the clinical onset of myelodysplastic disorder.

Clinical onset and operational service [37019]

36777 [2] the veteran received thorium dioxide (Thorotrast) at least one year before the clinical onset of the condition under consideration.

36779 — the veteran received thorium dioxide (Thorotrast) for an illness or injury which is identifiable.

[3]36780

36783 — the identified illness or injury, for which the veteran received thorium dioxide (Thorotrast), is causally related to eligible service. [9] [5]